Nav: Home

Roflumilast improves lung function after 6 months compared with placebo

October 22, 2012

Roflumilast was associated with significant improvements in lung function in patients with moderate and severe chronic obstructive pulmonary disease (COPD) after 6 months of treatment compared with placebo. Roflumilast is approved to reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

To examine the drug's impact on lung function, researchers from multiple institutions, including Baylor College of Medicine; Takeda Pharmaceuticals International GmbH; and Forest Research Institute, randomized 4,746 subjects to roflumilast (pooled intent-to-treat [ITT], n= 2511; moderate COPD, n=1184; severe COPD, n=1217) or placebo (pooled ITT, n=2235; moderate COPD, n=1098; severe COPD, n=1062). Baseline demographics were similar between treatment groups.

At 6 months, roflumilast increased pre- and postbronchodilator FEV1 by 66 mL and 67 mL, respectively, compared with placebo. Roflumilast, compared with placebo, also increased pre- and postbronchodilator FEV1 in subjects with moderate and severe COPD.

This study was presented during CHEST 2012, the annual meeting of the American College of Chest Physicians, held October 20 - 25, in Atlanta, Georgia.
-end-


American College of Chest Physicians

Related Copd Articles:

Treatment seeks to address exacerbations of COPD
A new study finds that delivery of oxygen via high-flow nasal tubes may help patients who experience exacerbations of chronic obstructive pulmonary disease (COPD).
Study reveals surprises concerning COPD and smoking
A new study challenges the widely accepted but oversimplified description of airway inflammation in smokers and patients with chronic obstructive pulmonary disease (COPD).
New guidelines for treatment and management of COPD exacerbations
A multi-disciplinary ERS/ATS task force of chronic obstructive pulmonary disease (COPD) experts has published comprehensive new guidelines on the treatment of COPD exacerbations.
New genetic markers for COPD discovered
In a new Research Letter published in Nature Genetics on Feb.
COPD -- what causes the lungs to lose their ability to heal?
In chronic obstructive pulmonary disease (COPD), the patients' lungs lose their ability to repair damages on their own.
More Copd News and Copd Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...